Targeting pro‐survival members of the BCL‐2 family is an attractive therapeutic option in MM but reliance on BCL‐2, MCL‐1 and BCL‐XL for survival has been shown to be variable (Touzeau et al 2014). This evidence concerns the gene BCL2 and Miyoshi myopathy.